Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 11/2023

20-10-2023 | Cardiovascular Disease in Gender Medicine | Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Contraception and Cardiovascular Effects: What Should the Cardiologist Know?

Authors: Anhthu Trinh, Ankit Vyas, Anna Roselle, Dhivya Velu, Lekha Hota, Madhavi Kadiyala

Published in: Current Cardiology Reports | Issue 11/2023

Login to get access

Abstract

Purpose of Review

Cardiovascular disease (CVD) is the leading cause of death in women. This review highlights contraceptive options and their effects on the cardiovascular system (CVS). It provides guidance to cardiologists to make informed decisions regarding the safety of contraceptive use and cardiovascular risk stratification in the care of women of childbearing age.

Recent Findings

Approximately 44% of American women live with some type of CVD. Many women use hormonal contraception during their lifetime. It is imperative that cardiologists have a robust understanding of the forms of contraception in current use and their cardiovascular effects.

Summary

This contemporary review provides a comprehensive summary of available contraceptive methods to practicing cardiologists and aims to be used as a resource to guide cardiovascular specialists on contraception in the context of cardiovascular disease.
Literature
1.
Long ME, Faubion SS, MacLaughlin KL, Pruthi S, Casey PM. Contraception and hormonal management in the perimenopause. J Womens Health 2002. 2015;24(1):3–10.
2.
Daniels K, Abma JC. Current contraceptive status among women aged 15–49: United States, 2017–2019. NCHS Data Brief. 2020;388:1–8.
3.
Skafar DF, Xu R, Morales J, Ram J, Sowers JR. Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab. 1997;82(12):3913–8.PubMed
4.
Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 1999;4(2):67–73.CrossRef
5.
Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception. 1998;57(5):315–24.
6.
Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception. 2001;64(5):295–9.CrossRefPubMed
7.
• Brito M, Nobre F, Vieira C. Hormonal contraception and cardiovascular system. Arq Bras Cardiol. 2011;1(96):e81–9. This article highlights the physiological effects of endogenous and exogenous hormones on the cardiovascular system.CrossRef
8.
9.
Zhu X, Bonet B, Gillenwater H, Knopp RH. Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis. Proc Soc Exp Biol Med Soc Exp Biol Med N Y N. 1999;222(3):214–21.CrossRef
10.
Jones DR, Schmidt RJ, Pickard RT, Foxworthy PS, Eacho PI. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J Lipid Res. 2002;43(3):383–91.CrossRefPubMed
11.
Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996;61(4):166–71.CrossRefPubMed
12.
13.
Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523–34.CrossRefPubMed
14.
Salem JE, Dureau P, Bachelot A, Germain M, Voiriot P, Lebourgeois B, et al. Association of Oral contraceptives with drug-induced QT interval prolongation in healthy nonmenopausal women. JAMA Cardiol. 2018;3(9):877–82.CrossRefPubMedPubMedCentral
15.
Shekhar S, Agrawal A, Pampori A, Lak H, Windsor J, Ramakrishna H. Mortality in adult congenital heart disease: analysis of outcomes and risk stratification. J Cardiothorac Vasc Anesth. 2022;36(8 Pt B):3379–88.
16.
17.
18.
Lindley KJ, BaireyMerz CN, Davis MB, Madden T, Park K, Bello NA, et al. Contraception and reproductive planning for women with cardiovascular disease: JACC focus seminar 5/5. J Am Coll Cardiol. 2021;77(14):1823–34.CrossRefPubMedPubMedCentral
19.
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin No. 196: thromboembolism in pregnancy. Obstet Gynecol. 2018;132(1):e1–17.
20.
21.
Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of hormonal contraception with depression. JAMA Psychiat. 2016;73(11):1154–62.CrossRef
22.
23.
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-621.CrossRefPubMed
24.
Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109(2 Pt 1):339–46.CrossRefPubMed
25.
Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: a systematic review. Contraception. 2016;94(6):678–700.CrossRefPubMed
26.
Chiara Del Savio M, De Fata R, Facchinetti F, Grandi G. Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol. 2020;13(7):685–94.CrossRefPubMed
27.
Allen RH, Cwiak CA, Kaunitz AM. Contraception in women over 40 years of age. CMAJ Can Med Assoc J. 2013;185(7):565–73.CrossRef
28.
Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ. 2011;25(343): d6423.CrossRef
29.
Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res. 2016;137:11–6.CrossRefPubMed
30.
Reed S, Koro C, DiBello J, Becker K, Bauerfeind A, Franke C, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2021;26(6):439–46.
31.
von Stockum S, Becker K, Bauerfeind A, Franke C, Fruzzetti F, Calaf J, et al. NOMAC-E2 compares to LNG combined oral contraceptives in women over forty: real-world PRO-E2 study. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2023;39(1):2166032.CrossRef
32.
33.
•• Curtis KM. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep [Internet]. 2016 [cited 2023 Feb 28];65. Available from: https://​www.​cdc.​gov/​mmwr/​volumes/​65/​rr/​rr6503a1.​htm. This reference gives guidelines for various conditions, including cardiovascular conditions, and their recommendations for contraception which was one of the main purposes of this article. The table in this article was updated in 2020.
34.
Johnson-Mallard V, Kostas-Polston EA, Woods NF, Simmonds KE, Alexander IM, Taylor D. Unintended pregnancy: a framework for prevention and options for midlife women in the US. Womens Midlife Health. 2017;3:8.CrossRefPubMedPubMedCentral
35.
Antinori S, Gholami GH, Versaci C, Cerusico F, Dani L, Antinori M, et al. Obstetric and prenatal outcome in menopausal women: a 12-year clinical study. Reprod Biomed Online. 2003;6(2):257–61.CrossRefPubMed
36.
Dinger J, Möhner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol. 2013;122(4):800–8.CrossRefPubMed
37.
Grandi G, Barra F, Ferrero S, Facchinetti F. Estradiol in non-oral hormonal contraception: a “long and winding road.” Expert Rev Endocrinol Metab. 2019;14(3):153–5.CrossRefPubMed
38.
Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol. 2000;95(5):736–44.
39.
Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart Br Card Soc. 2006;92(10):1520–5.CrossRef
40.
Swan L. Congenital heart disease in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2014;28(4):495–506.CrossRefPubMed
41.
Greutmann M, Pieper PG. Pregnancy in women with congenital heart disease. Eur Heart J. 2015;36(37):2491–9.CrossRefPubMed
42.
Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998;31(7):1650–7.CrossRefPubMed
43.
44.
Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol. 2014;64(15):1629–36.CrossRefPubMed
45.
Hilfiker-Kleiner D, Haghikia A, Masuko D, Nonhoff J, Held D, Libhaber E, et al. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail. 2017;19(12):1723–8.CrossRefPubMed
46.
Yaméogo NV, Samadoulougou AK, Kagambèga LJ, Kologo KJ, Millogo GRC, Thiam A, et al. Maternal and fetal prognosis of subsequent pregnancy in black African women with peripartum cardiomyopathy. BMC Cardiovasc Disord. 2018;18(18):119.CrossRefPubMedPubMedCentral
Metadata
Title
Contraception and Cardiovascular Effects: What Should the Cardiologist Know?
Authors
Anhthu Trinh
Ankit Vyas
Anna Roselle
Dhivya Velu
Lekha Hota
Madhavi Kadiyala
Publication date
20-10-2023
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 11/2023
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01981-9

Other articles of this Issue 11/2023

Current Cardiology Reports 11/2023 Go to the issue

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Long-Term Remote vs. Conventional Monitoring of Pacemakers: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

Obesity, Cardiorespiratory Fitness, and Cardiovascular Disease

Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Tailored to a Woman’s Heart: Gender Cardio-Oncology Across the Lifespan

Echocardiography (JM Gardin and AH Waller, Section Editors)

Contrast Echocardiography for Assessing Myocardial Perfusion

Cardio-Oncology (LA Baldassarre, Section Editor)

Advances in Screening for Radiation-Associated Cardiotoxicity in Cancer Patients

Congenital Heart Disease (RA Krasuski and G Fleming, Section Editors)

Novel Approaches to the Failing Congenital Heart
Image Credits